141 related articles for article (PubMed ID: 21507695)
1. [Value of positron emission tomography and computer tomography (PET/CT) for urologic malignancies].
Boujelbene N; Prior JO; Boubaker A; Azria D; Schaffer M; Gez E; Jichlinski P; Meuwly JY; Mirimanoff RO; Ozsahin M; Zouhair A
Cancer Radiother; 2011 Jul; 15(4):307-15. PubMed ID: 21507695
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers.
Zouhair A; Ozsahin M; Schaffer M; Albrecht S; Camus F; Jichlinski P; Mirimanoff RO; Bischof Delaloye A; Meuwly JY; Prior JO
Curr Med Chem; 2010; 17(23):2492-502. PubMed ID: 20491646
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography in urologic oncology.
Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
5. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; Courbon F; Edeline V; Helal BO; Rossi D; Villers A; ; ; ; ; ; ; ;
Bull Cancer; 2006 Dec; 93(12):1228-32. PubMed ID: 17191352
[No Abstract] [Full Text] [Related]
6. Possible role of FDG-PET in the evaluation of urologic malignancies.
Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
[TBL] [Abstract][Full Text] [Related]
7. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
[TBL] [Abstract][Full Text] [Related]
8. Advances in Imaging in Prostate and Bladder Cancer.
Srivastava A; Douglass LM; Chernyak V; Watts KL
Curr Urol Rep; 2017 Sep; 18(9):69. PubMed ID: 28718164
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography in uro-oncology.
Hain SF
Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
[TBL] [Abstract][Full Text] [Related]
10. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
[No Abstract] [Full Text] [Related]
11. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.
Machtens S; Serth J; Meyer A; Kleinhorst C; Ommer KJ; Herbst U; Kieruij M; Boerner AR
World J Urol; 2007 Aug; 25(4):341-9. PubMed ID: 17624533
[TBL] [Abstract][Full Text] [Related]
12. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
13. [Use of computer tomography in irradiation planning. 2. Comparison with the conventional roentgenologic technic in prostate and bladder cancers].
Oehler W; Hüttner J; Wiener A
Radiobiol Radiother (Berl); 1983; 24(3):269-77. PubMed ID: 6635159
[No Abstract] [Full Text] [Related]
14. PET/CT and radiotherapy in prostate cancer.
De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
Bouchelouche K; Oehr P
J Urol; 2008 Jan; 179(1):34-45. PubMed ID: 17997425
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives in the use of molecular imaging to target surgical treatments for genitourinary cancers.
Greco F; Cadeddu JA; Gill IS; Kaouk JH; Remzi M; Thompson RH; van Leeuwen FW; van der Poel HG; Fornara P; Rassweiler J
Eur Urol; 2014 May; 65(5):947-64. PubMed ID: 23957947
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography in urological malignancy.
Brush JP
Curr Opin Urol; 2001 Mar; 11(2):175-9. PubMed ID: 11224748
[TBL] [Abstract][Full Text] [Related]
19. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
20. Trends in PET Scan Usage for Imaging of Patients Diagnosed With Nonmetastatic Urologic Cancer.
Adejoro O; Alishahi A; Soubra A; Konety B
Clin Genitourin Cancer; 2016 Feb; 14(1):38-47.e1. PubMed ID: 26525859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
